The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Value-Based Insurance Design: By abandoning the archaic principle that all services must cost the same for all patients, we can move to a high-value health system.
Abstract
When everyone is required to pay the same out-of-pocket amount for health care services whose benefits depend on patient characteristics, there is enormous potential for both under- and overuse. Unlike most current health plan designs, Value-Based Insurance Design (VBID) explicitly acknowledges and responds to patient heterogeneity. It encourages the use of services when the clinical benefits exceed the cost and likewise discourages the use of services when the benefits do not justify the cost. This paper makes the case for VBID and outlines current VBID initiatives in the private sector as well as barriers to further adoption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2019) · AEA Papers and Proceedings · doi:10.1257/pandp.109.612 · Cited by 10,902
UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE
Arrow, K. J. (2003) · Uncertain Times · doi:10.2307/j.ctv11sn34h.6 · Cited by 4,078
The American Journal of Managed Care
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc · Cited by 3,237
Health insurance and the demand for medical care: evidence from a randomized experiment.
Manning, W. G., Newhouse, J. P., Duan, N., Keeler, E. B., Leibowitz, A. A., & Marquis, M. S. (1987) · PubMed · Cited by 2,478
Uncertainty and The Welfare Economics of Medical Care
Arrow, K. J. (2001) · Journal of Health Politics, Policy and Law · doi:10.1215/03616878-26-5-851 · Cited by 1,467
Free for All? Lessons from the RAND Health Insurance Experiment
Neuberg, L. G., Newhouse, J. P., & Group, I. E. (1995) · Southern Economic Journal · doi:10.2307/1061020 · Cited by 991
Cranor, C. W., Bunting, B. A., & Christensen, D. B. (2003) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658003321480713 · Cited by 728 · cited 1×
“An evaluation of the Asheville project (which included more than copay reduction) reported five-year outcomes that include marked increases in medication adherence, a two- to threefold increase in achieving diabetes performance measures, approximately a 50 percent decrease in average annual sick leave, and a trend in…”
MethodNewhouse, J. P., & Taylor, V. (1969) · Cited by 583
Pharmacy Benefits and the Use of Drugs by the Chronically Ill
Goldman, D. P. (2004) · JAMA · doi:10.1001/jama.291.19.2344 · Cited by 530
The Health Effects of Restricting Prescription Medication Use Because of Cost
Heisler, M., Langa, K. M., Eby, E. L., Fendrick, A. M., Kabeto, M. U., & Piette, J. D. (2004) · Medical Care · doi:10.1097/01.mlr.0000129352.36733.cc · Cited by 317
Self-citationThe effects of prescription drug cost sharing: a review of the evidence.
Gibson, T. B., Ozminkowski, R. J., & Goetzel, R. Z. (2005) · PubMed · Cited by 295
The value of health insurance: the access motive
Nyman, J. A. (1999) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00049-6 · Cited by 294
Impact Of Decreasing Copayments On Medication Adherence Within A Disease Management Environment
Chernew, M. E., Shah, M. R., Wegh, A., Rosenberg, S. N., Juster, I. A., Rosen, A. B., Sokol, M. C., Yu-Isenberg, K., & Fendrick, A. M. (2008) · Health Affairs · doi:10.1377/hlthaff.27.1.103 · Cited by 289
Self-citationInappropriate Use of Hospitals in a Randomized Trial of Health Insurance Plans
Siu, A. L., Sonnenberg, F. A., Manning, W. G., Goldberg, G. A., Bloomfield, E. S., Newhouse, J. P., & Brook, R. H. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611133152005 · Cited by 286
Fendrick, A. M., Smith, D. G., Chernew, M. E., & Shah, S. N. (2001) · PubMed · Cited by 184
Self-citationVarying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
Goldman, D. P., Joyce, G., & Karaca‐Mandic, P. (2006) · PubMed · Cited by 173
Ringel, J. S., Hosek, S. D., Vollaard, B., et al. (2002) · Cited by 142
Rosen, A. B., Hamel, M. B., Weinstein, M. C., Cutler, D., Fendrick, A. M., & Vijan, S. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-2-200507190-00007 · Cited by 135
Self-citationDeveloping A Center For Comparative Effectiveness Information
Wilensky, G. R. (2006) · Health Affairs · doi:10.1377/hlthaff.25.w572 · Cited by 134
Choudhry, N. K., Patrick, A. R., Antman, E. M., Avorn, J., & Shrank, W. H. (2008) · Circulation · doi:10.1161/circulationaha.107.735605 · Cited by 132
Rice, T., & Matsuoka, K. (2004) · Medical Care Research and Review · doi:10.1177/1077558704269498 · Cited by 117
The effects of prescription drug copayments on statin adherence.
Gibson, T. B., Mark, T. L., McGuigan, K. A., Axelsen, K. J., & Wang, S. S. (2006) · PubMed · Cited by 101
Reporting Clinical Trial Results To Inform Providers, Payers, And Consumers
Hayward, R. A., Kent, D. M., Vijan, S. S., & Hofer, T. P. (2005) · Health Affairs · doi:10.1377/hlthaff.24.6.1571 · Cited by 93
Reducing patient drug acquisition costs can lower diabetes health claims.
Mahoney, J. J. (2005) · PubMed · Cited by 88
Reconsidering the moral hazard-risk avoidance tradeoff.
Newhouse, J. (2006) · Journal of Health Economics · doi:10.1016/j.jhealeco.2006.06.003 · Cited by 76
Effect of a medication copayment increase in veterans with schizophrenia.
Zeber, J. E., Grazier, K. L., Valenstein, M. M., Blow, F. C., & Lantz, P. M. (2007) · PubMed · Cited by 73
Managed Consumerism In Health Care
Robinson, J. C. (2005) · Health Affairs · doi:10.1377/hlthaff.24.6.1478 · Cited by 67
Fendrick, A. M., & Chernew, M. E. (2006) · PubMed · Cited by 47
Self-citationMAGER, D. E., & Cox, E. R. (2007) · PubMed · Cited by 39
Incentive formularies and changes in prescription drug spending.
Landon, B. E., Rosenthal, M. B., Normand, S. T., et al. (2007) · PubMed · Cited by 33
Access Versus Excess: Value-Based Cost Sharing For Prescription Drugs
Kleinke, J. D. (2004) · Health Affairs · doi:10.1377/hlthaff.23.1.34 · Cited by 26
Effect of copayments on drug use in the presence of annual payment limits.
Kephart, G. C., Skedgel, C. D., SKETRIS, I. S., et al. (2007) · PubMed · Cited by 26
Effects of benefit design change across 5 disease states.
Brixner, D. I., Joish, V. N., Odera, G. M., Avey, S. G., Hanson, D. M., & Cannon, H. E. (2007) · PubMed · Cited by 24
Consumer response to dual incentives under multitiered prescription drug formularies.
Gilman, B. H., & Kautter, J. (2007) · PubMed · Cited by 24
Cited by
The Future of Disability in America
(2007) · National Academies Press eBooks · doi:10.17226/11898 · Cited by 567
Financial Toxicity of Cancer Care: It’s Time to Intervene
Yousuf Zafar, S. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv370 · Cited by 536
Dall, T. M., Gallo, P. D., Chakrabarti, R., West, T., Semilla, A. P., & Storm, M. V. (2013) · Health Affairs · doi:10.1377/hlthaff.2013.0714 · Cited by 529
Levers for addressing medical underuse and overuse: achieving high-value health care
Elshaug, A. G., Rosenthal, M. B., Lavis, J. N., Brownlee, S., Schmidt, H., Nagpal, S., Littlejohns, P., Srivastava, D., Tunis, S., & Saini, V. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32586-7 · Cited by 440
Brot-Goldberg, Z. C., Chandra, A., Handel, B. R., & Kolstad, J. T. (2017) · The Quarterly Journal of Economics · doi:10.1093/qje/qjx013 · Cited by 415
Metadata
- Authors
- Chernew, M. E., Rosen, A. B., & Fendrick, A. M.
- Venue
- Health Affairs
- Publisher
- Health Affairs Publishing, LLC
- Published
- 2007-01
- Volume
- 26
- Issue
- Suppl2
- Pages
- w195-w203
- ISSN
- 0278-2715 (ISSN-L)
- 1544-5208
- OpenAlex
- W2129906534
- Cited by
- 344
- References
- 34
- FWCI
- 67.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.